Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.

Abstract: The present invention provides novel compounds represented by the formula wherein R is an aliphatic straight chain or branched radical comprised of from 1 to 20 carbon atoms, or R is a polar esterifying group which may be represented by the formula (CHR1CYHX]nH wherein X is O or S; Y is selected from the group consisting of H, —OH, —COOH, CONH2, SO3H and PO3H2 and n is an integer of from 1 to 10, or R is selected from the group consisting of (i) acyl sulfonamide radicals represented by the formula (vi) Sulfonamide radicals represented by the formula SO2NR12 and (iii) wherein R1 is independently selected from the group consisting of hydrogen and alkyl radicals comprised from 1 to 20 carbon atoms and pharmaceutically-acceptable salts thereof. These compounds, and additional compounds wherein R may also be hydrogen, may be used in treating ocular hypertension and/or providing neuroprotection to the eye of the mammal.

Abstract: The invention relates to the use of Abnormal Cannabidiols in a combination with a drug selected from the group consisting of cholinergic agonists, chlolinesterase inhibitors, prostamides and prostaglandins and the like, or pharmaceutically acceptable salts or prodrugs thereof as potent ocular hypotensives. Said combinations are particularly suitable for the management of glaucoma.

Abstract: Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP4 receptor, or are prostaglandin EP4 antagonists.

Abstract: A low voltage different signaling (LVDS) includes an LVDS transmitter and an LVDS receiver. The LVDS transmitter includes a feedback compensation circuit, which adjusts and stabilizes the analog image signal to be transmitted to the LVDS receiver according to the voltage difference of the analog image signal and a base signal. The feedback compensation circuit includes a voltage-to-current converting circuit and a pair of current mirror circuits.

Abstract: The invention relates to the use of Abnormal Cannabidiols in a combination with a drug selected from the group consisting of ?-blockers, adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, chlolinesterase inhibitors, glutamate antagonists, prostamides and prostaglandins and the like, or pharmaceutically acceptable salts or prodrugs thereof as potent ocular hypotensives. Said combinations are particularly suitable for the management of glaucoma.

Abstract: The invention relates to the use of Abnormal Cannabidiols as neuroprotective agents. In particular said compounds are represented by the formula I wherein R is selected from the group consisting of (CH2)x wherein x is 0 or an integer of from 1 to 7.

Abstract: The invention relates to the use of Abnormal Cannabidiols as potent ocular hypotensives, and are particularly suitable for the management of glaucoma.

Abstract: A low voltage different signaling (LVDS) includes an LVDS transmitter and an LVDS receiver. The LVDS transmitter includes a feedback compensation circuit, which adjusts and stabilizes the analog image signal to be transmitted to the LVDS receiver according to the voltage difference of the analog image signal and a base signal. The feedback compensation circuit includes a voltage-to-current converting circuit and a pair of current mirror circuits.

Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.

Abstract: An assembly comprising a ceramic vane with a metal housing cast around the ends of the vane. The ceramic vane has dovetailed shaped grooves along its edges that extend from the vane's leading edge to its trailing edge. The housing is comprised of two spaced apart walls each having dovetailed protrusions for mating with the dovetail grooves in the vanes's edges. Upon the casting of the walls to the vane at least one surface of each dovetail groove comes in contact with at least one surface of the dovetail protrusion. A crushable coating is disposed between the vane's edges and the dovetail protrusions.

Abstract: Compounds of Formula 1, where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. In particular the compound PGF2&agr; 1-ethanolamide, having the formula was discovered to be present in mammalian tissue as a naturally occurring substance, was synthesized in a substantially pure form and was found to be effective for lowering intraocular pressure in the mammalian eye, but not acting through the FP receptor through which many ocular hypotensive prostaglandins act.

Abstract: The present invention provides a method of effecting vasodilation, comprising:administering to a warm blooded animal in need of such treatment, an effective amount of a (1,5-inter) aryl prostaglandin derivative represented by the Formula I ##STR1## wherein n is 0 or an integer of from 1 to 6, R is selected from the group of radicals represented by the formulae:CO.sub.2 R', CONR'.sub.2, CH.sub.2 OR' and SO.sub.2 NR'.sub.2 'wherein R' is hydrogen or a lower alkyl radical having from one to six carbon atoms; R" is hydrogen or an acyl radical having the formula (CO)R'" wherein R'" is a saturated or unsaturated acyclic hydrocarbon radical having from 1 to about 10 carbon atoms, or --(CH.sub.2).sub.m R"" wherein m is 0 or an integer of from 1 to 6 and R"" is an aliphatic ring having from 3 to 7 carbon atoms or an aryl group, e.g. phenyl, or a heteroaryl group, e.g.

Abstract: The present invention provides a method of effecting vasodilation, comprising:administering to a warm blooded animal in need of such treatment, an effective amount of a (1,5-inter) aryl prostaglandin derivative represented by the Formula I ##STR1## wherein n is 0 or an integer of from 1 to 6, R is selected from the group of radicals represented by the formulae:CO.sub.2 R', CONR'.sub.2, CH.sub.2 OR' and SO.sub.2 NR'.sub.2'wherein R' is hydrogen or a lower alkyl radical having from one to six carbon atoms; R" is hydrogen or an acyl radical having the formula (CO)R'" wherein R'" is a saturated or unsaturated acyclic hydrocarbon radical having from 1 to about 10 carbon atoms, or --(CH.sub.2).sub.m R"" wherein m is 0 or an integer of from 1 to 6 and R"" is an aliphatic ring having from 3 to 7 carbon atoms or an aryl group, e.g. phenyl, or a heteroaryl group, e.g.